SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Jubilant Pharmova’s step down arm signs, issues put option offer to Pierre Fabre Laboratories

19 Aug 2024 Evaluate

Jubilant Pharmova’s wholly owned subsidiary -- Jubilant Biosys’ (JBL) subsidiary -- Jubilant Biosys Innovative Research Services Pte, Singapore has signed and issued a ‘put option offer’ to Pierre Fabre Laboratories, which sets forth an offer to acquire 80% equity capital (around Euro 4.4 million over a period of 2 years) in a new company to be incorporated in France, which new company shall acquire Pierre Fabre’s R&D Centre (Including R&D Site and R&D activities) at Saint Julien, France.

The R&D centre has a capability of conducting discovery and preclinical development activities in immune-oncology. The facilities include research labs & office space including parking area surrounded by green field.

Pierre Fabre Laboratories may invest 20% equity capital (around Euro 1.1 million over a period of 2 years) in a new company for a maximum period of 5 years, during which time they may continue to provide support to the new company. In addition to that, Pierre Fabre Laboratories may also hire services from Jubilant Biosys aggregating to Euro 7 million for first 4 years post-closing date.

Jubilant Pharmova (formerly Jubilant Life Sciences) is a company engaged in pharmaceuticals, contract research and development services and proprietary novel drugs businesses.

Jubilant Pharmova Share Price

911.60 6.55 (0.72%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×